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ABSTRACT 
 
Sudden cardiac death is one of the leading causes of death in the western 
industrial nations. Most people are affected by coronary heart disease (coronary heart 
disease, CHD) or heart muscle (cardiomyopathy). These can lead to life-threatening 
cardiac arrhythmias. If the heartbeat is too slow due to impulse or conduction 
disturbances, cardiac pacemakers will be implanted. High-frequency and life-
threatening arrhythmias of the ventricles (ventricular tachycardia, flutter or fibrillation) 
cannot be treated with a pacemaker. In such cases, an implantable cardioverter-
defibrillator (ICD) is used, which additionally also provides all functions of a pacemaker. 
The implantation of a defibrillator is appropriate if a high risk of malignant arrhythmias 
has been established (primary prevention). If these life-threatening cardiac arrhythmias 
have occurred before and are not caused by a treatable (reversible) cause, ICD 
implantation will be used for secondary prevention. The device can stop these life-
threatening cardiac arrhythmias by delivering a shock or rapid impulse delivery 
(antitachycardic pacing) to prevent sudden cardiac death. Another area of application 
for ICD therapy is advanced heart failure (heart failure), in which both main chambers 
and / or different wall sections of the left ventricle no longer work synchronously. This 
form of cardiac insufficiency can be treated by electrical stimulation (cardiac 
resynchronization therapy, CRT). Since the affected patients are also at increased risk 
for sudden cardiac death, combination devices are usually implanted, which combine 
heart failure treatment by resynchronization therapy and the prevention of sudden 
cardiac death by life-threatening arrhythmia of the heart chambers (CRT-D device). An 
ICD is implanted subcutaneously or under the pectoral muscle in the area of the left 
collarbone. Like pacemaker implantation, ICD implantation is a routine, low-complication 
procedure today. 
 
 
Introduction 
An implantable cardioverter-
defibrillator (ICD) has been used as an 
effective mortality-reducing therapy for 
the prevention of sudden cardiac death 
for over 30 years. When choosing an 
ICD therapy, however, it must also be 
taken into account that complications 
(e.g. infections, thromboses, 
malfunctions) and inadequate shocks 
that are stressful for the patient may 
occur, so that careful evaluation of 
indication is essential. 
For the use ICD for protection 
against sudden cardiac death, two 
different forms of prevention are 
generally distinguished: 
1. Secondary Prevention, if an ICD is 
used after a so-called index event, 
which usually is a tachycardia-related 
cardiac arrest (or weaker symptoms 
such as (pre-) syncope or low blood 
pressure).  
2. Primary Prevention, when using an 
ICD in high-risk patients for sudden 
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cardiac death without an index event 
. 
The evaluation of the indication 
for ICD therapy follows the 
recommendations of the 2015 published 
guidelines of the European Society of 
Cardiology (ESC) for the management 
of patients with ventricular arrhythmias 
and for the prevention of sudden 
cardiac death.1 The following is an 
overview of the indications for ICD 
therapy: 
• Secondary prevention of ventricular 
fibrillation or ventricular tachycardia 
with clinical symptoms 
• Secondary prevention after 
syncope 
• Secondary prevention in case of 
persistent ventricular tachycardia 
(untreatable)  
• Primary prevention in patients with 
ventricular dysfunction 
• Dilated Cardiomyopathy (DCM) 
• Hypertrophic cardiomyopathy 
(HCM) 
• Long QT Syndrome (LQTS) 
• Short QT syndrome (SQTS) 
• Brugada syndrome 
• Catecholaminergic polymorphic 
ventricular tachycardia (CPVT)  
• Torsade de pointes tachycardia 
• Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
 
Secondary prevention 
In three large studies, the 
survival benefit of ICD use was 
demonstrated over the sole 
conservative treatment with 
antiarrhythmic drugs. While cardiac 
arrest patients were included in the 
CASH study (Cardiac Arrest Study, 
Hamburg),2 AVID (Antiarrhythmics 
versus Implantable Defibrillators)3 and 
CIDS (Canadian Implantable 
Defibrillator Study)4 also included 
patients with syncope (or other 
symptoms) and reduced ventricular 
ejection fractionwhere the  arrhythmia 
for the index event was not 
documented, but were inducible for 
ventricular tachyarrhythmias or 
monomorphic Tachycardias were found 
to be predictive. A meta-analysis of the 
3 studies showed a 28% reduction in 
the relative risk of death in ICD-treated 
patients.5 
There is a Class I indication for 
documented ventricular fibrillation or 
hemodynamicallyunstable ventricular 
tachycardia causing symptoms 
(cardiovascular arrest, cardiogenic 
shock, pulmonary edema, syncope, 
presyncope or very low blood pressure). 
Care must be taken to ensure that the 
clinical event causing the indication was 
not triggered by safely avoidable causes 
(eg WPW syndrome) or one-time 
causes (eg heart attack within the last 
48 hours). Also ICD implantation is 
recommended in patients with syncope 
caused most likely by ventricular 
tachyarrhythmia associated with a 
reduced left ventricular ejection fraction 
(LVEF) or a survived heart attack (with 
simultaneous inducibility of ventricular 
tachycardia as part of 
electrophysiological examination).1 
With persistent (more than 30 
seconds) ventricular tachycardias that 
are hemodynamically tolerated (i.e., 
"stable"), the study situation is much 
less clear. If necessary, the data from 
the AVID register can be used to prove 
the secondary prophylactic benefit of an 
ICD in this constellation.3 However, 
there is an expert opinion-based 
indication to consider the implantation of 
a defibrillator with stable ventricular 
tachycardia (evidence level C, class IIa 
according to ESC guidelines).1 
 
Primary prevention in patients 
with ventricular dysfunction 
Since most patients do not 
survive out-of-hospital cardiovascular 
arrest, the goal of primary prevention is 
to identify high-risk patients and implant 
defibrillators. According to current 
guidelines, patients with ventricular 
dysfunction LVEF < 35%, an ICD 
Implantation is recommended.1 
In patients with ischemic 
cardiomyopathy or after myocardial 
infarction, the mortality-reduction benefit 
has mainly been demonstrated by two 
prospective studies: the MADIT II study 
(Multicenter Automatic Defibrillators 
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Implantion Trial) and the SCD HeFT 
study (Sudden Cardiac Death in Heart 
Failure Trial).6,7 The evidence level of 
indication for defibrillator implantation in 
this patient population is A. By contrast, 
the benefit of ICD therapy is less well 
demonstrated in patients with non-
ischemic cardiomyopathy (DCM); The 
indication for ICD care is based on a 
meta-analysis by Desai et al.,8 which 
includes several small examinations, 
the DEFINITE study (Defibrillators in 
Non-Ischemic Cardiomyopathy 
Treatment Evaluation), and subgroups 
of SCD-HFT and COMPANION 
(Comparison of Medical Therapy, 
Pacing, and Defibrillation in Heart 
Failure).7-9 The DANISH study published 
in 2016 following the publication of the 
ESC guidelines does not find a clear 
survival advantage of ICD therapy in 
patients with systolic heart failure 
caused by coronary heart disease.10 
In the absence of randomized 
controlled trials, the authors of the 
current ESC guidelines do not 
recommend ICD implantation for 
primary prevention in NYHA Class I 
patients and in patients with a LVEF> 
35%.1 Generally, ICD implantation as 
primary prevention in patients with 
ventricular dysfunction is indicated only 
if optimized drug therapy has been 
performed for at least three months, the 
life expectancy in good functional status 
is more than one year and the ICD 
implantation is not < 40 days after a 
myocardial infarction.1 
 
Cardiomyopathies 
The indication for dilated 
cardiomyopathy (DCM) depends 
essentially on the conditions for 
secondary prevention or primary 
prevention in patients with ventricular 
dysfunction (see above).The secondary 
prophylactic indication for hypertrophic 
cardiomyopathy (HCM) obeys the 
principles already outlined above. 
Although there are no prospective 
randomized studies on ICD therapy in 
HCM, cohort studies and meta-analyzes 
show that fatal cardiac arrhythmias are 
often followed by surviving sudden 
cardiac arrest or persistent ventricular 
tachycardia.11 
Primary prophylactic ICD 
implantation in HCM is based on the 5-
year risk of sudden cardiac death, 
where a risk of> 6% represents a Class 
IIa and a risk of between 4% and 6% a 
Class IIb indication. This risk should be 
calculated using the HCM Risk SCD 
calculator, which relies on several risk 
factors: age, ventricular wall thickness, 
left atrial diameter, LV outflow gradient, 
cases of sudden cardiac death from 
close relatives, non-sustained 
ventricular tachycardia, and the 
occurrence of Syncope.12 
 
Congenital primary arrhyth-
mia syndromes 
In patients with long QT 
syndrome (LQTS) and surviving cardiac 
arrest or ventricular fibrillation, an 
implantable defibrillator is indicated as 
there is a high risk of recurrence.6 In the 
primary prevention of patients with 
LQTS on the other hand, beta-blockers 
are the main therapy. Since syncope or 
ventricle tachycardia is associated with 
an increased risk of subsequent cardiac 
arrest in beta-blockade,13,14 ICD 
implantation may be considered in 
these cases.1 
In patients with short QT 
syndrome (SQTS) who have survived 
cardiac arrest or ventricular fibrillation, 
or who have persistent ventricular 
tachycardia, there is an indication for 
ICD implantation as there is an 
increased likelihood of (further) life 
threatening cardiac events.15 
If Brugada syndrome is 
diagnosed, an implantable defibrillator is 
the only way to effectively reduce the 
risk of sudden cardiac death. ICD 
implantation is indicated when 
ventricular fibrillation, persistent 
ventricular tachycardia or 
cardiovascular arrest have been 
survived, or a spontaneous Brugada 
type-1 ECG has been identified with 
otherwise unexplained syncope.1,16 
Although ventricular fibrillation is 
inducible by electrophysiological 
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examination, ICD implantation may be 
considered.17 
In patients with catecho-
laminergic polymorphic ventricular 
tachycardia (CPVT), ICD implantation is 
indicated in addition to beta-blocker 
therapy if cardiac arrest, ventricular 
fibrillation, ventricular tachycardia, or 
recurrent syncope have already 
occurred.1 
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